MedTrace Logo

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

NCT00649389 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2500

Last updated 2019-01-09

Study results available
· View outcomes & findings →

Summary

To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.

Conditions

Interventions

DRUG

Olmesartan medoxomil

40mg olmesartan medoxomil

DRUG

Amlodipine

Amlodipine 10mg

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 25mg

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-04-30
Completion
2009-12-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00649389 on ClinicalTrials.gov